Calculate isotretinoin cumulative dose, track treatment progress, and monitor lab values. Includes dosing by severity, iPLEDGE reminders, and lab schedules.
The Isotretinoin (Accutane) Dose Calculator helps patients and providers track cumulative dosing, estimate treatment duration, and monitor laboratory safety parameters during isotretinoin therapy. Isotretinoin (13-cis-retinoic acid) remains the most effective treatment for severe nodulocystic acne, with long-term remission rates of 60-80% after a single course.
The key to durable remission is achieving an adequate cumulative dose — typically 120-150 mg/kg total, though recent evidence suggests higher cumulative doses (up to 220 mg/kg) are associated with lower relapse rates. This calculator computes your target cumulative dose based on body weight, tracks progress against that target, estimates remaining treatment duration at your current daily dose, and provides evidence-based dosing ranges by acne severity.
Additionally, this tool supports lab safety monitoring by flagging concerning ALT (liver function) and triglyceride elevations — the two most common lab abnormalities during isotretinoin therapy. It includes iPLEDGE REMS program reminders, monthly lab schedules, and clinical decision support for dose adjustments based on laboratory findings.
Tracking cumulative isotretinoin dosing is essential for treatment success. Under-dosing is the primary cause of acne relapse, while over-dosing increases side effect risk. This calculator eliminates guesswork and provides clear progress tracking so patients and providers can make informed dosing decisions. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain.
Target Cumulative Dose (mg) = Target (mg/kg) × Weight (kg). Dose per kg/day = Daily dose (mg) / Weight (kg). Cumulative dose = Daily dose × Days completed. Days remaining = Remaining dose / Daily dose. Standard target: 120-150 mg/kg total cumulative dose.
Result: 2,400 mg completed (34.3 mg/kg) of 8,400 mg target — 150 days remaining
At 40 mg/day for 60 days, cumulative dose is 2,400 mg (34.3 mg/kg). Target is 120 mg/kg × 70 kg = 8,400 mg. Remaining: 6,000 mg ÷ 40 mg/day = 150 more days (~5 months). Total course: ~7 months.
Isotretinoin's mechanism involves normalizing keratinocyte differentiation, dramatically reducing sebum production (by up to 90%), reducing Cutibacterium acnes colonization, and decreasing inflammation. The cumulative dose concept emerged from observations that relapse rates correlate inversely with total drug exposure. Strauss et al. established the 120 mg/kg guideline, but subsequent studies have shown continued benefit at higher cumulative doses.
The 120 mg/kg target represents the point where approximately 80% of patients achieve durable remission. Raising the target to 150 mg/kg improves this to approximately 85-90%. Some aggressive protocols targeting 220 mg/kg report relapse rates under 5%, though with increased side effect burden. The optimal target likely depends on individual factors including acne severity, sebum production, and response to treatment.
Almost all patients experience mucocutaneous dryness — cheilitis (dry lips) in virtually 100%, dry skin in 50-80%, and dry eyes in 20-30%. These are dose-dependent and reversible. Strategies include aggressive moisturization, humidifiers, preservative-free artificial tears, and occasional dose reduction for severe symptoms.
Musculoskeletal symptoms (arthralgias, myalgias, back pain) affect 15-30% of patients and can mimic the aches of the two major lab concerns: elevated triglycerides and transaminases. Routine blood work is essential in the first 2 months; after that, monitoring frequency can be reduced if values remain normal.
Isotretinoin is a Category X teratogen with devastating effects on fetal development, including craniofacial, cardiac, and CNS malformations. The iPLEDGE REMS program was implemented in 2006 to prevent fetal exposure and requires monthly pregnancy tests, two forms of contraception for patients of childbearing potential, and coordination between patients, prescribers, and pharmacies through a centralized online system.
The traditional target of 120 mg/kg comes from early studies by Strauss et al. More recent data (Blasiak 2013, Coloe 2011) suggest that 150 mg/kg and higher may reduce relapse rates from 20-30% to 10-15%. Some dermatologists now target 150-220 mg/kg for severe acne.
Yes — isotretinoin absorption nearly doubles when taken with a fatty meal (≥20g fat). Always take it with food to maximize bioavailability and reach your cumulative target more efficiently. Fasted absorption can be as low as 50% of fed absorption.
Most courses run 5-7 months at standard dosing (0.5-1.0 mg/kg/day). Treatment duration depends on the target cumulative dose divided by the daily dose. Lower daily doses extend the course but may have fewer side effects.
iPLEDGE is a mandatory REMS program for all isotretinoin prescribing in the US. Patients of childbearing potential must have monthly pregnancy tests, use two forms of contraception, and pick up prescriptions within a 7-day window. All patients must have a monthly check-in.
Stop isotretinoin if ALT exceeds 3× the upper limit of normal (>120 U/L) or fasting triglycerides exceed 500 mg/dL (pancreatitis risk). Mild elevations (1-2× ULN) can often be managed with dose reduction and retesting in 2-4 weeks.
Low-dose protocols (10-20 mg/day or 0.15-0.4 mg/kg/day) are increasingly used for moderate acne and adult acne. They have fewer side effects but require longer treatment (12-18 months) to reach the same cumulative target. Efficacy appears comparable in some studies.